203 related articles for article (PubMed ID: 35771632)
1. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2.
Li H; Wang Y; Lin K; Venkadakrishnan VB; Bakht M; Shi W; Meng C; Zhang J; Tremble K; Liang X; Song JH; Feng X; Van V; Deng P; Burks JK; Aparicio A; Keyomarsi K; Chen J; Lu Y; Beltran H; Zhao D
Cancer Res; 2022 Sep; 82(17):3088-3101. PubMed ID: 35771632
[TBL] [Abstract][Full Text] [Related]
2. Structural basis for the design of allosteric inhibitors of the Aurora kinase A enzyme in the cancer chemotherapy.
de Souza VB; Kawano DF
Biochim Biophys Acta Gen Subj; 2020 Jan; 1864(1):129448. PubMed ID: 31676293
[TBL] [Abstract][Full Text] [Related]
3. The AURKA/TPX2 axis drives colon tumorigenesis cooperatively with MYC.
Takahashi Y; Sheridan P; Niida A; Sawada G; Uchi R; Mizuno H; Kurashige J; Sugimachi K; Sasaki S; Shimada Y; Hase K; Kusunoki M; Kudo S; Watanabe M; Yamada K; Sugihara K; Yamamoto H; Suzuki A; Doki Y; Miyano S; Mori M; Mimori K
Ann Oncol; 2015 May; 26(5):935-942. PubMed ID: 25632068
[TBL] [Abstract][Full Text] [Related]
4. Aurora A kinase and its activator TPX2 are potential therapeutic targets in KRAS-induced pancreatic cancer.
Gomes-Filho SM; Dos Santos EO; Bertoldi ERM; Scalabrini LC; Heidrich V; Dazzani B; Levantini E; Reis EM; Bassères DS
Cell Oncol (Dordr); 2020 Jun; 43(3):445-460. PubMed ID: 32193808
[TBL] [Abstract][Full Text] [Related]
5. Glioma pathogenesis-related protein 1 induces prostate cancer cell death through Hsc70-mediated suppression of AURKA and TPX2.
Li L; Yang G; Ren C; Tanimoto R; Hirayama T; Wang J; Hawke D; Kim SM; Lee JS; Goltsov AA; Park S; Ittmann MM; Troncoso P; Thompson TC
Mol Oncol; 2013 Jun; 7(3):484-96. PubMed ID: 23333597
[TBL] [Abstract][Full Text] [Related]
6. Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.
Kari V; Mansour WY; Raul SK; Baumgart SJ; Mund A; Grade M; Sirma H; Simon R; Will H; Dobbelstein M; Dikomey E; Johnsen SA
EMBO Rep; 2016 Nov; 17(11):1609-1623. PubMed ID: 27596623
[TBL] [Abstract][Full Text] [Related]
7. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Aurora Kinase A Induces Necroptosis in Pancreatic Carcinoma.
Xie Y; Zhu S; Zhong M; Yang M; Sun X; Liu J; Kroemer G; Lotze M; Zeh HJ; Kang R; Tang D
Gastroenterology; 2017 Nov; 153(5):1429-1443.e5. PubMed ID: 28764929
[TBL] [Abstract][Full Text] [Related]
9. Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.
Mohan P; Castellsague J; Jiang J; Allen K; Chen H; Nemirovsky O; Spyra M; Hu K; Kluwe L; Pujana MA; Villanueva A; Mautner VF; Keats JJ; Dunn SE; Lazaro C; Maxwell CA
Oncotarget; 2013 Jan; 4(1):80-93. PubMed ID: 23328114
[TBL] [Abstract][Full Text] [Related]
10. Discovery of N-benzylbenzamide-based allosteric inhibitors of Aurora kinase A.
Lee H; Kim E; Hwang N; Yoo J; Nam Y; Hwang I; Park JG; Park SE; Chung KS; Won Chung H; Song C; Ji MJ; Park HM; Lee IK; Lee KT; Joo Roh E; Hur W
Bioorg Med Chem; 2024 Mar; 102():117658. PubMed ID: 38460487
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.
Shah KN; Bhatt R; Rotow J; Rohrberg J; Olivas V; Wang VE; Hemmati G; Martins MM; Maynard A; Kuhn J; Galeas J; Donnella HJ; Kaushik S; Ku A; Dumont S; Krings G; Haringsma HJ; Robillard L; Simmons AD; Harding TC; McCormick F; Goga A; Blakely CM; Bivona TG; Bandyopadhyay S
Nat Med; 2019 Jan; 25(1):111-118. PubMed ID: 30478424
[TBL] [Abstract][Full Text] [Related]
12. Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck.
Lee JW; Parameswaran J; Sandoval-Schaefer T; Eoh KJ; Yang DH; Zhu F; Mehra R; Sharma R; Gaffney SG; Perry EB; Townsend JP; Serebriiskii IG; Golemis EA; Issaeva N; Yarbrough WG; Koo JS; Burtness B
Clin Cancer Res; 2019 Jun; 25(11):3430-3442. PubMed ID: 30755439
[TBL] [Abstract][Full Text] [Related]
13. AurkA/TPX2 co-overexpression in nontransformed cells promotes genome instability through induction of chromosome mis-segregation and attenuation of the p53 signalling pathway.
Naso FD; Polverino F; Cilluffo D; Latini L; Stagni V; Asteriti IA; Rosa A; Soddu S; Guarguaglini G
Biochim Biophys Acta Mol Basis Dis; 2024 Apr; 1870(4):167116. PubMed ID: 38447882
[TBL] [Abstract][Full Text] [Related]
14. CHD1 and SPOP synergistically protect prostate epithelial cells from DNA damage.
Zhu Y; Wen J; Huang G; Mittlesteadt J; Wen X; Lu X
Prostate; 2021 Jan; 81(1):81-88. PubMed ID: 33022763
[TBL] [Abstract][Full Text] [Related]
15. Chromatin Regulator CHD1 Remodels the Immunosuppressive Tumor Microenvironment in PTEN-Deficient Prostate Cancer.
Zhao D; Cai L; Lu X; Liang X; Li J; Chen P; Ittmann M; Shang X; Jiang S; Li H; Meng C; Flores I; Song JH; Horner JW; Lan Z; Wu CJ; Li J; Chang Q; Chen KC; Wang G; Deng P; Spring DJ; Wang YA; DePinho RA
Cancer Discov; 2020 Sep; 10(9):1374-1387. PubMed ID: 32385075
[TBL] [Abstract][Full Text] [Related]
16. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors.
Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S
J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263
[TBL] [Abstract][Full Text] [Related]
17. SIX3, a tumor suppressor, inhibits astrocytoma tumorigenesis by transcriptional repression of AURKA/B.
Yu Z; Sun Y; She X; Wang Z; Chen S; Deng Z; Zhang Y; Liu Q; Liu Q; Zhao C; Li P; Liu C; Feng J; Fu H; Li G; Wu M
J Hematol Oncol; 2017 Jun; 10(1):115. PubMed ID: 28595628
[TBL] [Abstract][Full Text] [Related]
18. Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer.
Ton AT; Singh K; Morin H; Ban F; Leblanc E; Lee J; Lallous N; Cherkasov A
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167327
[TBL] [Abstract][Full Text] [Related]
19.
Jillson LK; Rider LC; Rodrigues LU; Romero L; Karimpour-Fard A; Nieto C; Gillette C; Torkko K; Danis E; Smith EE; Nolley R; Peehl DM; Lucia MS; Costello JC; Cramer SD
Mol Cancer Res; 2021 Jul; 19(7):1123-1136. PubMed ID: 33846123
[TBL] [Abstract][Full Text] [Related]
20. Allosteric modulation of AURKA kinase activity by a small-molecule inhibitor of its protein-protein interaction with TPX2.
Janeček M; Rossmann M; Sharma P; Emery A; Huggins DJ; Stockwell SR; Stokes JE; Tan YS; Almeida EG; Hardwick B; Narvaez AJ; Hyvönen M; Spring DR; McKenzie GJ; Venkitaraman AR
Sci Rep; 2016 Jun; 6():28528. PubMed ID: 27339427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
